What centenarian families reveal about healthy aging: a rare gene variant that dials down inflammation

Healthy aging — long a holy grail of biology — has come a small step closer thanks to a clue extracted from a new genomic study. The Long Life Family Study (LLFS), run by Boston University School of Medicine with European partners, has scanned the genomes of nearly 5,000 individuals across 588 families with members past 90, hunting for rare variants linked to healthier aging.

The work was published in Nature Aging. Importantly, researchers did not focus on lifespan alone but on healthspan — the years lived free of major chronic disease. Observation has long suggested that very long-lived people accumulate chronic conditions later than their peers, and often less severely.

The headline finding: a rare protein-altering variant inside the TNFRSF11A gene. The gene encodes the RANK receptor, which sits at the intersection of bone turnover and immune signalling. About three per cent of LLFS participants carried the variant, against roughly 0.3 per cent in matched controls — a tenfold enrichment.

Carriers had markedly lower blood markers of inflammation than non-carriers — C-reactive protein, interleukin-6 and TNF-alpha all measurably reduced. "These people are aging as if their inflammatory system has been reset," said co-author Stacy Andersen of Boston University. "The age-related drift toward chronic inflammation simply isn't happening in them."

Chronic low-grade inflammation — what the field has labelled "inflammaging" — is increasingly seen as the shared biological substrate of age-related diseases: cardiovascular disease, cancer, dementia, type 2 diabetes and sarcopenia. If a single point in that process is tractable, intervention could in principle benefit multiple diseases at once.

To guard against a single-cohort fluke, the team replicated the finding in two independent datasets — the Framingham Heart Study and the Leiden Longevity Study in the Netherlands. The TNFRSF11A variant was significantly associated with healthy aging in both, lowering the chance that the signal is an artefact of any one family group.

The RANK pathway is, for drug developers, a familiar target. Denosumab — marketed as Prolia — is a monoclonal antibody that blocks RANK ligand, used today for osteoporosis. The new study hints that drugs aimed slightly differently at the same pathway — particularly at its inflammatory branch — might curb several age-related diseases together. That, however, remains a distant goal.

The authors are direct about the limitations. LLFS participants are predominantly of European ancestry; the variant's effect in other populations needs separate study. Aging is also overwhelmingly multifactorial; one mutation's contribution is woven through diet, socioeconomic status, environment and the actions of hundreds of other genes.

In the short term, the public-health prescription is unchanged: a Mediterranean-style diet, regular moderate exercise, no smoking, limited alcohol, strong social ties. These remain what scientists consistently call the durable longevity stack. A genetic drug is a possible future, not a present one.

The lasting value of the LLFS study is the conceptual one. It strengthens the case that healthy aging is not pure luck but the outcome of biology that can, in principle, be targeted. As Andersen put it: "If the inflammatory system does not have to stiffen with age, then if we can map the chemistry of that protection, we can in principle reproduce it therapeutically."